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Patients with non–ST-segment elevation acute coronary
syndrome (NSTE-ACS) who are managed without revas-
cularization represent a heterogenous and understudied
population. Several studies have highlighted the higher
morbidity and mortality in such patients, and data show
a relative 50% increase in risk-adjusted mortality (1,2).
Strikingly similar higher rates of ischemic events worldwide
have been reported, even after accounting for variations in
early revascularization use in different regions of the world;
these ﬁndings suggest that this is a high-risk population, and
yet these patients are undertreated with evidence-based
therapies (2,3).See page 2249The recommendation to use dual-antiplatelet therapy
(DAPT) with clopidogrel to prevent future ischemic events
in these conservatively treated patients is based on the ﬁnd-
ings of a single study, the CURE (Clopidogrel in Unstable
Angina to Prevent Recurrent Events Trial Investigators:
Effects of Clopidogrel in Addition to Aspirin in Patients
With Acute Coronary Syndromes Without ST-Segment
Elevation) trial, which was conducted more than a decade ago
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(MI), or stroke after DAPT versus aspirin alone, and its
ﬁndings were consistent among medically managed patients
(n ¼ 7,985) and those who had undergone revascularization
procedures (n ¼ 4,577). The management of patients with
NSTE-ACS has evolved signiﬁcantly since that trial. The
U.S. contribution to the CURE trial was minimal; therefore,
it is reasonable to explore the validity of these ﬁndings in
current U.S. practice.
In this issue of the Journal, Solomon et al. (5) performed
a retrospective cohort study of conservatively managed pa-
tients with NSTE-ACS within an integrated managed care
consortium based in northern California between 2003
and 2008. After applying exclusion criteria to mimic the
CURE trial criteria, these investigators evaluated longitu-
dinal outcomes (z2.5 years) among 16,365 patients with
NSTE-ACS; 5,961 (36%) of these patients were receiving
clopidogrel treatment forz6 months on average. Outcomes
were compared in a propensity-score matched cohort (n ¼
8,562), and they showed a signiﬁcant reduction in the
occurrence of death or MI (13.5% vs. 17.4%, hazard ratio
[HR]: 0.74 [95% conﬁdence interval [CI]: 0.66 to 0.84])
after clopidogrel use, driven mainly by mortality reduction.
The ﬁndings of this “real world” study are compelling
for several reasons. First, the study illustrates once again that
adherence to clopidogrel remains low, despite a class Ia
indication for the use of clopidogrel. Second, it reafﬁrms
that the beneﬁt of clopidogrel persists for a longer duration
after hospital discharge (6). However, unlike in the CURE
trial, the majority of the beneﬁt of clopidogrel was driven by
a reduction in all-cause mortality (8.3% vs. 13.0%), whereas
MI rates appeared similar (6.7% vs. 7.2%). Although spec-
ulative, the lack of signal on MI probably relates to the
low detection of MI in clinical practice compared with
closely monitored clinical trials. Finally, the overall observed
beneﬁt of clopidogrel appeared to occur mainly in pati-
ents with non–ST-segment elevation myocardial infarction
(NSTEMI), but it was less pronounced in patients with
unstable angina (HR: 0.67 vs. 1.25; pint < 0.01). Again,
these ﬁndings are in contrast to those of the CURE trial,
in which outcomes were similar between patients with and
without elevated cardiac markers. One possible explanation
is the difference in diagnostic criteria used for MI (i.e.,
use of troponin instead of creatine kinase-myocardial band
[CK-MB]). As such, a signiﬁcant proportion of patients
with unstable angina in the CURE trial would currently be
classiﬁed as having NSTEMI. Another possible explanation
could be that some patients in the group with unstable
angina were in fact patients with chest pain attributable to
nonatherosclerotic causes who would not be expected to
beneﬁt from clopidogrel.
One of the most intriguing ﬁndings of the current study
was the beneﬁt seen in older patients, with signiﬁcant in-
teractions for patients >70 years of age (HR: 0.70 vs. 0.88;
pint ¼ 0.04). This interaction was not observed in the
CURE trial (4) or in more recent trials with either prasugrel
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2259(7) or ticagrelor (8). However, the major beneﬁt of ticagrelor
over clopidogrel among older patients was also mortality
related. This ﬁnding, in conjunction with the current ﬁnd-
ings, suggests that there may be substantial beneﬁt in
treating older patients with DAPT.
The current study has several important limitations. First,
because of the retrospective, nonrandomized study design,
some of the treatment beneﬁt of clopidogrel can be attributed
to unmeasured and/or residual confounding. Second, al-
though the investigators presume to have compared DAPT
with aspirin, this is in fact speculative because actual aspirin
use was unknown. Third, longitudinal follow-up data on
stroke or bleeding events were not collected, and these
data affect the net risk/beneﬁt ratio for the use of DAPT,
particularly in older patients. Fourth, a subgroup analysis of
patients with continued clopidogrel for >12 months was
not performed, and data on its beneﬁt are sparse. Finally,
including patient data over the years 2009 to 2012 would
have made the results even more up to date with contem-
porary practice.
Novel, faster-acting, and more potent antiplatelet agents
have been developed. Two of these agents, prasugrel
(a thienopyridine similar to clopidogrel) and ticagrelor
(a reversible P2Y12 receptor-blocker), have been tested in
patients with NSTE-ACS who were managed without
revascularization. The TRILOGY-ACS (Targeted Platelet
Inhibition to Clarify the Optimal Strategy to Medically
Manage Acute Coronary Syndromes) trial compared pra-
sugrel with clopidogrel in addition to aspirin in medically
managed patients with NSTE-ACS who were either
<75 years of age (n ¼ 7,243; prasugrel 10 mg) or 75 years
of age (n ¼ 2,083; prasugrel: 5 mg). The investigators found
no difference in the composite of death from cardiovascular
causes, nonfatal MI, or stroke during a median follow-up
of 17.1 months (9). Although the main trial results were
neutral, prasugrel was of beneﬁt among patients who un-
derwent catheterization (and thus had known atheroscle-
rosis) before randomization; in the overall cohort, a
separation was seen beyond a year in clinical outcomes in
favor of prasugrel (10). The safety and efﬁcacy of ticagrelor
for medically managed patients with ACS were explored in
a secondary analysis from the PLATO (Platelet Inhibition
and Patient Outcomes) trial. Study results showed a sig-
niﬁcant reduction in the composite endpoint of cardiovas-
cular death, MI, and stroke after ticagrelor versus clopidogrel
(12.0% vs. 14.3%; HR: 0.85, 95% CI: 0.73 to 1.00; p ¼
0.04), as well as in overall mortality (6.1% vs. 8.2%,
p ¼ 0.01). However, 40% of this “noninvasively” treated
group of patients was managed with revascularization during
the study period. Thus, this cohort was not entirely
conservatively treated (11). The incidence of total bleeding
events was not statistically different, although it was
numerically higher (11.9% vs. 10.3%; p ¼ 0.08).
The ﬁnal answer on the safety and efﬁcacy of ticagrelor
in preventing long-term cardiovascular events in patients
with a history of MI (including those who were managedconservatively) may come from the PEGASUS (Prevention
of Cardiovascular Events [eg, Death From Heart or Vascular
Disease, Heart Attack, or Stroke] in Patients With Prior
Heart Attack Using Ticagrelor Compared to Placebo on
a Background of Aspirin) trial (NCT01225562), which
targets to enroll 21,000 patients and randomizes patients
to either ticagrelor (90 or 60 mg twice daily) or placebo.
The primary goal of this study is to reduce the composite
of cardiovascular death, MI, or nonfatal stroke for up to
44 months. Thus, although ﬁndings are promising, the su-
periority of other novel antiplatelet agents over clopidogrel
still remains to be proven in patients with NSTE-ACS who
are managed without revascularization. Clopidogrel there-
fore remains the mainstay of therapy in these patients.
In conclusion, the paper by Solomon et al. (5) reafﬁrms
that even with the existence of guidelines to help optimize
care, implementation of these guidelines by treating phy-
sicians and institutions remain suboptimal. The results of
the study also suggest that in a “real world” setting, the
continued use of clopidogrel for several months after hos-
pital discharge is of clear beneﬁt to patients with NSTE-
ACS, particularly in patients with NSTEMI and in older
patients. We hope that this new body of evidence will
sway physicians who continue to withhold clopidogrel to
consider further implementation of clopidogrel use into
their practice to help improve outcomes in these high-risk
patients with ACS who do not undergo revascularization
procedures.
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